Boston Scientific Stock Surges on Strong Results, Outlook; CFO To Retire

Shares of Boston Scientific (BSX) rose sharply Wednesday after the firm posted first-quarter results that topped analysts’ estimates.

The Marlborough, Mass.-based medical technology firm reported adjusted earnings per share (EPS) of $0.75 on revenue of $4.66 billion. Analysts surveyed by Visible Alpha expected $0.67 and $4.57 billion, respectively.

For the full year, Boston Scientific sees adjusted EPS of $2.87 to $2.94 and sales up 15% to 17%, above Visible Alpha projections.

“We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio,” CEO Mike Mahoney said. “We remain well-positioned for the future as we continue to focus on meaningful innovation, clinical science and the execution of our category leadership strategy to drive differentiated growth and performance for the long-term.”

The firm also announced Wednesday that CFO Dan Brennan “has elected to retire following nearly 30 successful years with the company.” Brennan will leave his role at the end of June but “is expected to remain with Boston Scientific as a senior advisor through early October 2025.” 

Boston Scientific shares surged about 7% in early trading Wednesday, amid a broader market rally. (Read Investopedia’s live coverage of today’s market action here.)